| answer text |
<p>The Department is investing over £1 billion a year in health research through the
National Institute for Health Research (NIHR). The NIHR supports a wide portfolio
of research on antimicrobial resistance (AMR) through various funding streams. In
the United Kingdom, investment includes £32 million of capital funding to support
AMR research, £19.1 million for AMR research at four NIHR Biomedical Research Centres,
and £8.8 million for two NIHR Health Protection Research Units on Healthcare Associated
Infections and Antimicrobial Resistance.</p><p>The NIHR also supports research into
AMR in low and middle-income countries (LMICs), with official development assistance
(ODA) funding through the NIHR Global Health Research programme. Investment includes
support for the NIHR Global Health Research Unit on Genomic Surveillance of Antimicrobial
Resistance, and the NIHR Global Health Research Group on Genomic Surveillance of Malaria
in West Africa.</p><p>Working through partnerships with other UK funders, the NIHR
Global Health Research programme also supports cross-Research Council initiatives
including one led by the Medical Research Council for research into AMR in a global
context, and another led by the Economic and Social Research Council to expand understanding
of how behaviour within and beyond the healthcare system impacts on AMR.</p><p>In
addition, the Department has allocated over £50 million of ODA over five years to
AMR research through the Global AMR Innovation Fund. This research is delivered through
a range of mechanisms and delivery partners, including research councils such as the
Biotechnology and Biological Sciences Research Council and Innovate UK, and international
partners including the Wellcome Trust, Bill and Melinda Gates Foundation, the United
States and German governments, and Canada’s International Development Research Centre.</p>
|
|
